Profound Medical to Release Second Quarter 2022 Financial Results on August 4 – Conference Call to Follow
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) will release its Q2 2022 financial results after market close on August 4, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) will release its Q2 2022 financial results after market close on August 4, 2022. A conference call is scheduled for 4:30 PM ET to discuss these results and recent business developments. The company focuses on customizable, incision-free therapies for diseased tissue using technologies like TULSA-PRO® and Sonalleve®, which have received various international approvals, including FDA clearance and CE marking.
Positive
- Technologies TULSA-PRO® and Sonalleve® are CE marked and FDA cleared.
- TULSA-PRO® provides customizable, radiation-free ablation.
- Sonalleve® is being explored for additional treatment markets.
Negative
- None.
Details
News Market Reaction – PROF
The recorded move for PROF in the trading session of this news was +8.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, July 14, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2022 financial results after market close on Thursday, August 4, 2022.
Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
| Second Quarter 2022 Results Conference Call Details: | |
| Date: | Thursday, August 4, 2022 |
| Time: | 4:30 p.m. ET |
| Live Call Toll-Free: | 1-866-374-5140 (PIN: 23122874#) |
| Live Call International: | 1-404-400-0571 (PIN: 23122874#) |
The call will also be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (“BPH”). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.